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ABSTRACT
Background: Intake of n-3 polyunsaturated fatty acids (n-3 PUFAs) lowers the risk of atherosclerotic car-
diovascular events, particularly ischemic heart disease. In addition, the ratio of eicosapentaenoic acid (EPA;
n-3 PUFA) to arachidonic acid (AA; n-6 PUFA) has recently been recognized as a risk marker of cardiovas-
cular disease. In contrast, the prognostic impact of the EPA/AAratio on patients with heart failure (HF) remains
unclear.
Methods and Results: A total of 577 consecutive patients admitted for HF were divided into 2 groups
based on median of the EPA/AA ratio: low EPA/AA (EPA/AA <0.32 mg/dl, n = 291) and high EPA/AA
(EPA/AA ≥0.32, n = 286) groups. We compared laboratory data and echocardiographic findings and fol-
lowed cardiac mortality. Although body mass index, blood pressure, B-type natriuretic peptide, hemoglobin,
estimated glomerular filtration rate, total protein, albumin, sodium, C-reactive protein, and left ventricular
ejection fraction did not differ between the 2 groups, cardiac mortality was significantly higher in the low
EPA/AA group than in the high EPA/AA group (12.7 vs 5.9%, log-rank P = .004). Multivariate Cox pro-
portional hazard analysis revealed that the EPA/AA ratio was an independent predictor of cardiac mortality
(hazard ratio 0.677, 95% confidence interval 0.453–0.983, P = .041) in patients with HF.
Conclusion: The EPA/AA ratio was an independent predictor of cardiac mortality in patients with HF;
therefore, the prognosis of patients with HF may be improved by taking appropriate management to control
the EPA/AA balance. (J Cardiac Fail 2016;22:962–969)
Key Words: Heart failure, n-3 polyunsaturated fatty acids, eicosapentaenoic acid to docosahexaenoic acid
ratio, prognosis.
Heart failure (HF) remains one of the major causes of car-
diovascular morbidity and mortality, despite therapeutic
advances in its treatment. The cardiovascular protective effects
of seafood consumption and long-chain n-3 polyunsaturat-
ed fatty acid (n-3 PUFA) intake(eg, plaque stabilization,
antiarrhythmic and hemodynamic effects) have been
reported.1–6 The balance between dietary n-3 and n-6 fatty
acids, especially a low serum ratio of eicosapentaenoic acid
(EPA; n-3 PUFA) to arachidonic acid (AA; n-6 PUFA) may
be strongly associated with increased risk of cardiovascular
disease (CVD).1,7 Although AA increases inflammation, plate-
let aggregation, and vasoconstriction through cyclooxygenase
and lipoxygenase, EPA impairs inflammatory eicosanoid
derived from AA, platelet aggregation, and vasodilatation. EPA
competes or cooperates with AA, and thus the balance of EPA
and AA may be important.1 In addition, the EPA/AA ratio has
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a linear relationship with the ratio of prostaglandin I3 and pros-
taglandin I2 to thromboxane A2.1 Therefore, the EPA/AA ratio
has recently been recognized as a risk marker of CVD in-
cluding myocardial infarction, sudden cardiac death, stroke,
and thromboembolism in various populations.1,8–11 However,
the association between circulating levels of EPA/AA ratio
and cardiac mortality in patients with HF still remains unclear.
In addition, such an association may vary depending upon
several clinical backgrounds, such as age, gender, HF etiol-
ogy, comorbidities, and treatments.10,12–16 Furthermore, n-3
PUFA also attracts attention as a therapeutic target1,10 to reduce
the residual risk of CVD after low-density cholesterol-
lowering therapy with statins, which is common in the
management of CVD and/or HF.17,18 In the Japan EPA Lipid
Intervention Study (JELIS) study, the administration of EPA
and statins in dyslipidemia patients resulted in a significant
reduction in the risk of CVD events when the EPA/AA ratio
was >0.75 (hazard ratio [HR] 0.83, P = .031).19
Thus, the aim of the present study was to investigate the
associations between the EPA/AA ratio and cardiac mortal-
ity in patients with HF, with a focus on patients’ clinical
backgrounds (especially in HF patients with or without statins).
Methods
Subjects and Study Protocol
This was a prospective observational study that enrolled con-
secutive symptomatic HF patients who were hospitalized to treat
decompensated HF at Fukushima Medical University between
2009 and 2013. The diagnosis of decompensated HF was defined
by several cardiologists based on the Framingham criteria.20
Patients with acute coronary syndrome, on dialysis, or under-
going n-3 PUFA treatment were excluded. Patients who were
selected for this study were divided into 2 groups based on the
median value of the EPA/AA ratio: those with high EPA/AA
(EPA/AA ≥ 0.32, n = 286) and those with low EPA/AA (EPA/
AA < 0.32, n = 291).Afasting blood sample was obtained from
each patient within 24 hours of admission, and the serum levels
of fatty acids were blindly measured at SRL Co., Ltd. (Tokyo,
Japan) using a gas chromatrophy-flame ionization detector system
(6890N; Agilent Technologies, Tokyo, Japan).21 We per-
formed several examinations on admission, such as general
laboratory tests and echocardiography, and compared the pa-
rameters between the 2 groups. Comorbidities were also defined
by several attending physicians. Hypertension was defined as
the recent use of antihypertensive drugs, systolic blood pres-
sure >140 mmHg, and/or diastolic blood pressure >90 mmHg.
Diabetes was defined as the recent use of insulin or antidia-
betic drugs, a fasting blood glucose value >126 mg/dl, and/or
a hemoglobin A1c value >6.5%. Dyslipidemia was defined as
the recent use of cholesterol-lowering drugs, a triglyceride value
>150 mg/dl, a low-density lipoprotein (LDL) cholesterol
value >140 mg/dl, and/or a high-density lipoprotein choles-
terol value <40 mg/dl. Chronic kidney disease was defined as
an estimated glomerular filtration rate <60 ml/min/1.73 m2.22
Anemia was defined as a hemoglobin level <12.0 g/dl in females
and <13.0 g/dl in males.23 Reduced left ventricular ejection frac-
tion (LVEF) was defined as less than 50%. The patients were
followed up until March 2015 for cardiac mortality, which was
the primary outcome of our study. Cardiac death was con-
firmed by independent experienced cardiologists as death either
from worsened HF in accordance with the Framingham criteria,20
ventricular fibrillation documented by electrocardiograph or im-
plantable devices, or acute coronary syndrome. This follow-
up was performed blindly to the analyses of this study. Status
and dates of death were obtained from the patients’ medical
records or their referring cardiologists. Survival time was defined
as from the date of hospitalization until the date of death or
last follow-up. We could follow-up on all patients. Written in-
formed consent was obtained from all study subjects. The study
protocol was approved by the ethical committee of Fukushima
Medical University. The investigation conforms with the prin-
ciples outlined in the Declaration of Helsinki. Reporting of the
study conforms to Strengthening the Reporting of Observa-
tional Studies in Epidemiology along with references to
Strengthening the Reporting of Observational Studies in Epi-
demiology and the broader Enhancing the Quality and
Transparency of Health Research guidelines.24
Echocardiography
Echocardiography was performed blindly by an experi-
enced echocardiographer using standard techniques. The
echocardiographic parameters we investigated included in-
terventricular septum thickness, left ventricular dimension,
posterior wall thickness, LVEF, left atrial volume, the ratio
of early transmitral flow velocity to mitral annular velocity,
inferior vena cava diameter, peak systolic pulmonary artery
pressure, and right ventricular fractional area change.25 LVEF
was calculated using a modification of Simpson’s method.
Early transmitral flow velocity to mitral annular velocity was
calculated by transmitral Doppler flow and tissue Doppler
imaging. Tissue Doppler imaging was obtained from the average
of lateral and septal annulus velocities. Systolic pulmonary
artery pressure was calculated by adding the right atrial pres-
sure (estimated by the diameter and collapsibility of the inferior
vena cava) to the systolic trans tricuspid pressure gradient.25
The right ventricular fractional area change, defined as (end
diastolic area − end systolic area)/end diastolic area × 100, is
a measure of right ventricular systolic function.25 All record-
ings were performed on ultrasound systems (ACUSON Sequoia,
Siemens Medical Solutions USA, Inc., Mountain View, CA).
Statistical Analysis
Normally distributed data are presented as mean ± stan-
dard deviation, and non-normally distributed data are presented
as the median (inter-quartile range). Categorical variables are
expressed as numbers and percentages. The chi-square test
was used for comparisons of categorical variables. Data of
the 2 groups were compared using the independent Student
t test for normally distributed data and the Mann-Whitney U
test for nonnormally distributed data. The Kaplan-Meier method
was used for presenting cardiac mortality; the log-rank test
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was used for initial comparisons. Univariate and multivari-
ate Cox proportional hazard analyses were used to analyze
predictors of cardiac mortality adjusting for clinical vari-
ables that were different between the 2 groups: age, NewYork
Heart Association (NYHA) class, glomerular filtration rate,
high-density lipoprotein, and triglyceride. The proportional
hazard assumption for the Cox model was checked by ex-
amining log-minus-log–transformed Kaplan-Meier estimates
of the survival curves for the 2 groups plotted against time to
follow-up. These curves help in identifying nonproportionality
patterns in hazard function such as convergence (difference
in risk between the 2 groups decreases with time), diver-
gence, or crossing of the curves. In addition, the Schoenfeld
test for the violation of proportional hazards, which assesses
the correlation between scaled residuals and time, was also
conducted. To assess potential heterogeneity of associations
between circulating levels of EPA/AA ratio and cardiac mor-
tality, we also conducted subgroup analyses. Interactions
between EPA/AA ratio and clinically relevant variables that
are known to affect the risk of cardiac mortality in patients
with HF (age >65 years of age, male gender, NYHA func-
tional class III or IV, reduced LVEF, ischemic etiology, diabetes,
atrial fibrillation, chronic kidney disease, anemia, and use of
statins) were estimated by a Cox proportional hazard regres-
sion model and are shown in a Forest plot. P < .05 was
considered statistically significant for all comparisons. These
analyses were performed using a statistical software package
(SPSS, version 21.0, IBM, Armonk, NY).
Results
The clinical features of the study subjects are summa-
rized in Table 1. The low EPA/AA group patients were of a
lower age and had a higher prevalence of NYHA class III or
IV than the high EPA/AA group. In contrast, blood pres-
sure, heart rate, presence of reduced LVEF, etiology,
comorbidity, and medications did not differ between the 2
groups. Comparisons of the laboratory and echocardiographic
data between the 2 groups are shown in Table 2. The low EPA/
AA group had lower EPA, docosahexaenoic acid, and high-
density lipoprotein as well as higher levels of arachidonic acid,
dihomo-γ-linoleic acid and triglyceride. In contrast, hemo-
globin, B natriuretic peptide, C-reactive protein, total protein,
albumin, sodium, glucose, hemoglobin A1c, LDL cholester-
ol, oxidative LDL cholesterol, and echocardiographic
parameters did not differ between the 2 groups.
During the follow-up period (mean 710 days), there were
54 cardiac deaths, including 39 from worsening HF, 10 from
ventricular fibrillation, and 5 from acute coronary syn-
drome (37 and 17 in the low EPA/AA group and high EPA/
AA group, respectively). As shown in Fig. 1, cardiac mortality
was significantly higher in the low EPA/AA group than in
the high EPA/AA group (P = .004). A Cox proportional hazard
model was used to examine the prognostic value of the low
EPA/AA ratio in patients with HF (Table 3). We confirmed
that the Cox models supported the assumption of propor-
tional hazards. In the multivariate analysis after adjusting for
Table 1. Comparisons of Clinical Features Between High-EPA/AA and Low-EPA/AA Groups (N = 577)
High-EPA/AA
(≥0.32, n = 286)
Low-EPA/AA
(<0.32, n = 291) P Value
Age (y) 70.2 ± 11.4 64.2 ± 15.7 <.001
Male (n, %) 186 (65.0) 186 (63.9) .779
Body mass index (kg/cm2) 22.9 ± 3.7 23.1 ± 3.9 .589
Systolic blood pressure (mmHg) 127.2 ± 32.8 126.4 ± 31.9 .790
Diastolic blood pressure (mmHg) 70.8 ± 19.7 72.7 ± 22.1 .263
Heart rate (beats/min) 79.3 ± 27.4 81.7 ± 24.1 .266
NYHA class III or IV (n, %) 44 (15.4) 64 (22.0) .042
Reduced EF (n, %) 158 (55.2) 171 (58.8) .393
Etiology .433
Ischemic etiology (n, %) 72 (25.2) 80 (27.5)
Valvular (n, %) 96 (33.6) 79 (27.1)
Cardiomyopathy (n, %) 80 (28.0) 82 (28.2)
Others (n, %) 38 (13.3) 50 (17.2)
Comorbidity
Hypertension (n, %) 224 (78.3) 221 (75.9) .497
Diabetes (n, %) 115 (40.2) 118 (40.5) .934
Dyslipidemia (n, %) 231 (80.8) 242 (83.2) .455
Atrial fibrillation (n, %) 116 (40.6) 106 (36.4) .308
Chronic kidney disease (n, %) 177 (61.9) 171 (58.8) .443
Anemia (n, %) 162 (56.6) 167 (57.4) .857
Medications
RAS inhibitors (n, %) 226 (79.0) 224 (77.0) .553
β-blockers (n, %) 233 (81.5) 230 (79.0) .463
Diuretics (n, %) 200 (69.9) 204 (70.1) .964
Inotropics (n, %) 37 (12.9) 43 (14.8) .523
Statins (n, %) 118 (41.3) 116 (39.9) .733
Antidiabetic drugs (n, %) 69 (24.1) 68 (23.4) .831
AA, arachidonic acid; EPA, eicosapentaenoic acid; NYHA, New York Heart Association; RAS, renin-angiotensin-aldosterone system.
964 Journal of Cardiac Failure Vol. 22 No. 12 December 2016
clinical variables including age, NYHA class, glomerular fil-
tration rate, high-density lipoprotein, and triglyceride (Table 3),
EPA/AA ratio (as a continuous variable), and low-EPA/AA
group (as a categorical variable, vs high-EPA/AA group) were
independent predictors of cardiac mortality in patients with
HF (EPA/AA ratio, HR 0.677, 95% confidence interval [CI]
0.453–0.983, P = .041; low EPA/AA group, HR 2.468, 95%
CI 1.097–5.549, P = .029). Then, we focused on the pres-
ence of ischemic etiology. Irrespective of ischemic or
nonischemic etiology (Fig. 2), cardiac mortality was signifi-
cantly higher in the low EPA/AA group than in the high EPA/
AA group. In addition, we focused on the presence of statin
therapy (Fig. 3), cardiac mortality was significantly higher
in the low EPA/AA group than in the high EPA/AA group
in patients with HF taking statins (P = .003), and not in pa-
tients with HF not taking statins (P = .193). Furthermore, to
assess potential heterogeneity of impact of low EPA/AA ratio
on cardiac mortality, we conducted subgroup analyses and
examined interaction terms (Fig. 4). There were no interac-
tions except for a significant interaction with statins use
(P = .042) in associations of low EPA/AA and cardiac mor-
tality between subgroups.
Table 2. Laboratory and Echocardiographic Data
High-EPA/AA
(n = 286)
Low-EPA/AA
(n = 291) P Value
Laboratory data
EPA/AA ratio 0.55 ± 0.23 0.20 ± 0.07 <.001
Eicosapentaenoic acid (mg/dl) 86.8 ± 38.5 33.9 ± 14.4 <.001
Arachidonic acid (mg/dl) 156.5 ± 42.4 174.0 ± 60.5 <.001
Dihomo-γ-linolenic acid (mg/dl) 29.5 ± 12.7 32.4 ± 14.7 .010
Docosahexaenoic acid (mg/dl) 150.5 ± 50.0 107.0 ± 38.0 <.001
Hemoglobin (g/dl) 12.5 ± 2.1 12.7 ± 2.4 .507
BNP (pg/ml)* 337.0 (497) 317.4 (532) .286
Estimated GFR (ml/min/1.73 m2) 53.3 ± 22.3 57.4 ± 25.9 .077
C-reactive protein (mg/dl)* 0.17 (1) 0.25 (1) .127
Total protein (g/dl) 7.0 ± 0.7 6.9 ± 0.9 .178
Albumin (g/dl) 3.7 ± 0.6 3.7 ± 0.6 .089
Sodium (mEq/l) 138.6 ± 3.6 139.0 ± 3.4 .201
Glucose (g/dl) 125.6 ± 54.3 126.1 ± 56.5 .910
Hemoglobin A1c (%) 5.8 ± 1.0 5.8 ± 1.1 .801
Total cholesterol (mg/dl) 182.1 ± 40.1 176.0 ± 43.6 .169
HDL cholesterol (mg/dl) 53.8 ± 23.4 47.7 ± 19.4 .009
LDL cholesterol (mg/dl) 103.0 ± 35.0 104.9 ± 37.9 .588
Triglyceride (mg/dl) 113.8 ± 63.3 129.8 ± 94.1 .044
Oxidative LDL (mg/dl) 109.0 ± 38.1 111.1 ± 50.0 .667
Echocardiographic data
Interventricular septum thickness (mm) 11.5 ± 3.2 11.0 ± 2.6 .219
LV end-diastolic dimension (mm) 53.1 ± 10.6 53.8 ± 11.1 .447
LV end-systolic dimension (mm) 39.2 ± 13.1 40.8 ± 13.5 .163
Posterior wall thickness (mm) 11.2 ± 2.6 11.1 ± 2.6 .488
LV ejection fraction (%) 48.2 ± 15.9 46.7 ± 17.0 .327
Left atrial volume (ml) 90.7 ± 64.4 85.5 ± 54.2 .371
Mitral valve E/E′ 15.5 ± 7.3 16.5 ± 9.9 .241
Inferior vena cava diameter (mm) 15.0 ± 4.9 15.4 ± 5.3 .383
SPAP (mmHg) 31.0 ± 16.1 32.0 ± 17.3 .546
RV-FAC (%) 42.7 ± 16.6 41.0 ± 13.9 .359
BNP, B-type natriuretic peptide; EPA/AA ratio, eicosapentaenoic acid to arachidonic acid ratio; GFR, glomerular filtration rate; HDL, high-density lipo-
protein; LDL, low-density lipoprotein; LV, left ventricular; mitral valve E/E′, ratio of the peak transmitral velocity during early diastole to the peak mitral
valve annular velocity during early diastole; RV-FAC, right ventricular fractional area change; SPAP, systolic pulmonary artery pressure.
*Data are presented as median (interquartile range).
Fig. 1. Comparison of cardiac mortality between the low and high
EPA/AA groups. Kaplan-Meier analysis for cardiac mortality in pa-
tients with HF (n = 577). Cardiac mortality was significantly higher
in the low EPA/AA group than in the high EPA/AA group (P = .004).
AA, arachidonic acid; EPA, eicosapentaenoic acid.
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Table 3. Cox Proportional Hazard Model of Cardiac Death in HF: Impact of EPA/AA
Event
Cardiac death (N = 54/577) HR 95% CI P Value
EPA/AA ratio (+1 SD increase) unadjusted 0.660 0.462–0.943 .023
EPA/AA ratio (+1 SD increase) adjusted model* 0.677 0.453–0.983 .041
Low EPA/AA (vs high EPA/AA) unadjusted 2.262 1.273–4.020 .005
Low EPA/AA (vs high EPA/AA) adjusted model* 2.468 1.097–5.549 .029
HR, hazard ratio; SD, standard deviation. Other abbreviations as in Table 2.
*Adjusted model: adjusted for age, New York Heart Association class, glomerular filtration rate, high-density lipoprotein, and triglyceride.
Fig. 2. Cardiac mortality with or without ischemic etiology. Kaplan-Meier analysis for cardiac mortality (A) with ischemic etiology (n = 152)
and (B) without ischemic etiology (n = 425). Cardiac mortality was significantly higher in the low EPA/AA group than in the high EPA/AA
groups irrespective of ischemic or nonischemic etiologies. Abbreviations as in Fig. 1.
Fig. 3. Cardiac mortality with or without statins. Kaplan-Meier analysis for cardiac mortality (A) without statins (n = 343) and (B) with
statins (n = 234). Cardiac mortality was significantly higher in the low EPA/AA group than in the high EPA/AA group in HF patients with
statins (P = .003), but not in HF patients without statins (P = .193). Abbreviations as in Fig. 1.
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Discussion
To the best of our knowledge, the present study is the first
to show that patients with HF with a low circulating EPA/
AA ratio exhibited higher cardiac mortality. This impact was
found to be more distinct when patients with HF took statins.
The circulating level of n-3 PUFA is inversely associated
with HF incidence in those of the American general popu-
lation aged >65 years without prevalent CVD (HR 0.51,
P = .003).12 A Japanese epidemiological study showed an
inverse association between n-3 PUFA intake and cardiovas-
cular mortality, especially HF.26
Multiple physiological effects of n-3 PUFA in multiple
tissues, including the heart, liver, vasculature, and circulat-
ing cells, have been reported.3 The n-3 PUFA can improve
mitochondrial function and adenosine triphosphate genera-
tion. This can reduce blood pressure, heart rate, cardiac
remodeling,26–28 cardiac fibrosis, inflammation, atheroscle-
rotic plaque formation, platelet aggregation and thrombotic
factors, arrhythmic tendencies, and sudden death. It can also
improve cardiac systolic and diastolic function, myocardial
efficiency, endothelial function, blood lipid concentrations,
and autonomic function, and increase stroke volume and
oxygen consumption at peak exercise.2–4 The molecular mecha-
nisms include effects on cellular function including improved
membrane function, improved ion channel function, im-
proved nuclear receptor function and transcription factors, and
increased nitric oxide.2,3 In the present study, we could not
explain why blood pressure, heart rate, C-reactive protein, and
echocardiographic parameters were not different between the
2 groups, or why the low EPA/AA group had more cardiac
deaths. The association between n-3 PUFA and arrhythmia
may play an important role.2–4,29,30
Supplementation of n-3 PUFA in patients with CVD have
been reported.5,6,19,31–35 In a Gruppo Italiano per lo Studio della
Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione
trial from Italy, a 30% reduction in CVD mortality and a 45%
reduction in sudden cardiac death were observed in patients
who received n-3 PUFA (1.0 g/d) after myocardial infarction.6,31
In JELIS, patients with dyslipidemia who received both statin
and n-3 PUFA (1.8 g/d) had a 19% reduction in major cor-
onary events, but no significant sudden cardiac death reduction
was observed.19 In the GISSI-HF trial, before n-3 PUFA supple-
mentation, circulating n-3 PUFA levels in patients with HF
were inversely related to C-reactive protein, pentraxin-3,
adiponectin, natriuretic peptide, and troponin levels.32,33 EPA
supplementation has recently been reported to improve LVEF
with an increased EPA/AA ratio and reduced inflammatory
Fig. 4. Forrest plot with subgroup analyses for cardiac mortality. There were no interactions, except for a significant interaction with statins
use (P = .042), in associations between low EPA/AA and cardiac mortality between subgroups; hazard ratio of 5.328 (P = .008) with statin
use and hazard ratio of 1.562 (P = .196) without statin use. LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.
Other abbreviations as in Fig. 1.
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cytokines.21 On the contrary, recent meta-analysis revealed
that there was insufficient evidence of a secondary preven-
tive effect of n-3 PUFA supplements against cardiovascular
events in patients with CVD.34 Several confounders includ-
ing dose of n-3 PUFA, underlying CVD and comorbidities,
race, gender, and other factors may affect the impact of n-3
PUFA on CVD outcomes. The potential effects of n-3 PUFA
supplementation on the prognosis of HF are controversial and
require further investigation.3,4
Study Limitations
The present study has several limitations. First, the present
study, which was conducted as a prospective observational
study in a single institution with homogenous racial mix and
a relatively small number of subjects, might be insufficient
to accurately estimate the association between EPA/AA ratio
and mortality in patients with HF. However, diagnosis of
cardiac death was accurately made by our experienced car-
diologists. Although we analyzed using multivariate Cox
proportional hazard regression analyses and subgroup anal-
yses under consideration of multiple confounding factors, the
effects of the differences in clinical backgrounds between the
2 groups might not be completely adjusted; thus, the present
results should be viewed as preliminary and potentially lim-
iting the generalizability of the findings. Further studies with
a larger population are needed. Second, we did not measure
and consider any changes in the EPA/AA ratio, and only the
baseline EPA/AA ratio at admission was used for the anal-
yses. Third, our study did not elucidate whether an increased
EPA/AA ratio has a causal role in the adverse outcome, nor
did it clarify the mechanisms underlying the association. Our
data suggest that a lowered EPA/AA ratio is a potential
biomarker that may be helpful in the risk stratification of pa-
tients with HF. Future studies to determine the causal
relationship and the impact of an increased EPA/AA ratio and
develop treatment strategies in reducing mortality in pa-
tients with HF are required.
Conclusions and Perspectives
The EPA/AA ratio was an independent predictor of cardiac
mortality in patients with HF. This effect was found to be more
distinct when patients with HF took statins. Although it is not
well-known whether EPA supplementation improves prog-
nosis in patients with HF, taking appropriate management to
control the EPA/AA balance may reduce the residual risk of
patients with HF.
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